You haven't noticed RAP are finally gaining traction for ResAppDx-EU revenue which even you know is massive after you previously invested in this revolutionary and disruptive medical device for respiratory consultation (might be why Pfizer decided to make their move after Q4's result and continue growth last quarter if they are serious about entering the digital medical market) and RAP haven't even broken into the market for chronic respiratory management of Asthma (for all age demographic) and COPD (for adult).
NO-Vote support statement - draft 3, page-30
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #